[{"orgOrder":0,"company":"Lumicks","sponsor":"Glycostem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lumicks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lumicks \/ Lumicks","highestDevelopmentStatusID":"4","companyTruncated":"Lumicks \/ Lumicks"}]

Find Clinical Drug Pipeline Developments & Deals by Lumicks

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Glycostem will assess their NK cells using LUMICKS’ z-Movi to gain new insights into the cell avidity and functional properties of their cells. Avidity is a new parameter that is crucial to understand immune cells better and choose the most potent ones...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 30, 2020

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Glycostem Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank